Gapping down
In reaction to disappointing earnings/guidance:
PRIM -47.5%,
QLYS -23.9%,
ACRX -23.8%, (provides Zalviso regulatory update; notes its request for a Type B meeting with the FDA was denied),
CVLT -13.2%,
ONDK -9.6%,
EOX -7.7%,
SGY -7.6%,
EIGI -7.5%,
URG -5.4%,
XNCR -5.2%,
RGR -4.4%,
PTCT -4.3%,
KLIC -4.3%,
EMR -4.2%,
INVN -3.9%,
SNHY -3.7%,
PQ -3.4%,
KMT -3.2%,
OTTR -2.7%,
MCEP -2.6%,
MDU -2.6%,
BALT -2.1%,
ANIP -2.1%,
LSCC -1.8%,
HSBC -1.8%,
EIGI -1.3%
M&A news:
AVP -0.8% (having trouble finding a buyer, according to NY Post)
Other news:
ACRX -23.8% (co's request for a meeting with the FDA was denied; FDA reiterated that an additional clinical study will be required for Zalviso),
HELI -3.5% (announced appointment of Lee Eckert as successor CFO, effective July 16, 2015),
ACHC -2.7% (announces a proposed offering of 4.5 mln shares of common stock ),
MYCC -1.8% (announces secondary offering of 11 mln shares of common stock by a selling shareholder ),
VRSK -1.5% (announces a proposed $675 mln offering of common stock ),
EGLE -1.2% (disclosed departure of COO Alexis P. Zoullas)
Analyst comments:
LUX -4.1% (downgraded to Mkt Perform from Outperform at Raymond James),
GNW -2.8% (downgraded to Underweight from Equal-Weight at Morgan Stanley),
AOL -2.7% (downgraded to Sell from Neutral at Goldman),
STM -1.7% (downgraded to Neutral from Buy at BofA/Merrill),
BIDU -1.6% (downgraded to Neutral from Overweight at JP Morgan),
VECO -1.3% (downgraded to Outperform from Buy at Credit Agricole),
MFRM -1.1% (downgraded to Neutral from Overweight at Piper Jaffray),
MSI -0.7% (downgraded to Sell from Neutral at Goldman)
Click here to read the full comment.Portfolio Ticker Matches: SCANX
